中國同輻(01763.HK)與乾隆國際簽署戰略合作協議 積極探索核醫療相關產品科研、產業化方面的合作
格隆匯6月8日丨中國同輻(01763.HK)宣佈,中國同輻於2025年6月7日與乾隆國際控股有限公司("乾隆國際")簽署戰略合作協議。雙方將基於乾隆國際擬在國內投資建設腫瘤治療機構,推廣並深耕BNCT(硼中子俘獲治療技術)以及其他核醫療裝備、放射性藥品、智慧核醫學解決方案的國內、國際市場應用。雙方將積極探索核醫療相關產品科研、產業化方面的合作,以科技創新提升兩岸民生健康福祉,實現兩岸高端核醫學產業的雙向奔赴。
乾隆國際爲在香港設立的國際投資機構,專注於生物科技、數字健康,特殊營養食品等領域的創新創業的成果轉化和股權投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.